



National Health (Minimum Stockholding) Determination 2023

PB 65 of 2023

made under subsection 99AEKC(2) of the

National Health Act 1953

Compilation No. 8

Compilation date: 1 May 2024

Includes amendments: F2024L00502

Registered: 7 May 2024

Prepared by the Office of Parliamentary Counsel, Canberra

About this compilation

This compilation

This is a compilation of the *National Health (Minimum Stockholding) Determination 2023* that shows the text of the law as amended and in force on 1 May 2024 (the **compilation date**).

The notes at the end of this compilation (the **endnotes**) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the Register for the compiled law.

Self-repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

Part 1—Preliminary	1
1 Name	1
3 Authority	1
4 Definitions	1
5 Usual PBS demand.....	1
Part 2—Minimum stockholding requirement	3
6 Applicable quantity of a brand of a pharmaceutical item	3
Schedule 1—Applicable quantity of a brand of a pharmaceutical item	4
Endnotes	43
Endnote 1—About the endnotes	43
Endnote 2—Abbreviation key	44
Endnote 3—Legislation history	45
Endnote 4—Amendment history	46

Part 1—Preliminary

1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Determination 2023*.
- (2) This instrument may also be cited as PB 65 of 2023.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Definitions

In this instrument:

Act means the *National Health Act 1953*.

brand has the same meaning as in Part VII of the Act.

data collection period has the same meaning as in the *National Health (Pharmaceutical Benefits) Regulations 2017*.

pharmaceutical benefit has the same meaning as in Part VII of the Act.

pharmaceutical item has the same meaning as in Part VII of the Act.

pricing quantity has the same meaning as in Part VII of the Act.

usual demand, when used in relation to a brand of a pharmaceutical item, means the usual demand for the brand of the pharmaceutical item within the meaning of section 99AEKC of the Act.

usual PBS demand, when used in relation to a brand of a pharmaceutical item, means the usual PBS demand for the brand of the pharmaceutical item ascertained in accordance with section 5.

5 Usual PBS demand

- (1) The usual PBS demand for a brand of a pharmaceutical item for a month in a data collection period for that brand is the number of packs of the brand supplied during the data collection period (*the reference period*) before the previous data collection period for the brand divided by the number of months in the reference period.
- (2) For the purposes of subsection (1) the number of packs of the brand supplied during a data collection period is taken to be:

Section 5

- (a) the number of packs of the brand supplied as pharmaceutical benefits during that period; and
 - (b) adjusted as if the size of the pack equals the pricing quantity of the brand.
- (3) For the purposes of this section, a brand of pharmaceutical item to which section 99ADHC and therefore 99AEKA of the Act applies, but to which section 99ADD of the Act does not apply, is treated as if data collection periods applied to the brand, and as if the start day for the first data collection period for the brand was the day on which that brand was first determined under subsection 85(6) of the Act.

Part 2—Minimum stockholding requirement

6 Applicable quantity of a brand of a pharmaceutical item

For the purposes of subparagraphs 99AEKC(1)(a)(ii) and (1)(b)(ii) of the Act, if a brand of a pharmaceutical item is specified in an item of column 4 of the table in Schedule 1 to this instrument, the quantity ascertained in accordance with column 5 of that item is the applicable quantity of the brand of the pharmaceutical item.

Schedule 1—Applicable quantity of a brand of a pharmaceutical item

Note: See section 6.

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Acamprosate	Tablet (enteric coated) containing acamprosate calcium 333 mg	Oral	Acamprosate Viatris	after 30 July 2024—4 months stock by reference to usual demand of both Acamprosate Viatris and Acamprosate Mylan added together
Acarbose	Tablet 100 mg	Oral	Acarbose Viatris	4 months stock by reference to usual demand of both Acarbose Viatris and Acarbose Mylan added together
Acarbose	Tablet 100 mg	Oral	GLYBOSAY	2 months stock by reference to usual demand
Acarbose	Tablet 50 mg	Oral	Acarbose Viatris	after 30 July 2024—4 months stock by reference to usual demand of both Acarbose Viatris and Acarbose Mylan added together
Acarbose	Tablet 50 mg	Oral	GLYBOSAY	2 months stock by reference to usual demand
Allopurinol	Tablet 100 mg	Oral	Allosig	3 months stock by reference to usual demand
Allopurinol	Tablet 100 mg	Oral	Zyloprim	3 months stock by reference to usual demand
Allopurinol	Tablet 300 mg	Oral	Zyloprim	4 months stock by reference to usual demand

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Amino acid formula with vitamins and minerals without phenylalanine	Oral gel 85 g, 30 (PKU squeezie)	Oral	PKU squeezie	0 months stock by reference to usual PBS demand
Amisulpride	Oral solution 100 mg per mL, 60 mL	Oral	Solian Solution	4 months stock by reference to usual PBS demand
Amitriptyline	Tablet containing amitriptyline hydrochloride 10 mg	Oral	ENTRIP	4 months stock by reference to usual demand
Amitriptyline	Tablet containing amitriptyline hydrochloride 25 mg	Oral	APX-Amitriptyline	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand
Amitriptyline	Tablet containing amitriptyline hydrochloride 25 mg	Oral	ENTRIP	4 months stock by reference to usual demand
Amitriptyline	Tablet containing amitriptyline hydrochloride 50 mg	Oral	APX-Amitriptyline	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Amitriptyline	Tablet containing amitriptyline hydrochloride 50 mg	Oral	ENTRIP	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand
Amoxicillin	Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL	Oral	Amoxil	4 months stock by reference to usual PBS demand
Amphotericin B	Lozenge 10 mg	Oral	Fungilin	4 months stock by reference to usual PBS demand
Anakinra	Injection 100 mg in 0.67 mL single use pre-filled syringe	Injection	Kineret	6 months stock by reference to usual PBS demand
Anastrozole	Tablet 1 mg	Oral	Arimidex	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand
Aripiprazole	Tablet 10 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand
Aripiprazole	Tablet 10 mg	Oral	Aripic Aripiprazole	between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand
Aripiprazole	Tablet 15 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand
Aripiprazole	Tablet 20 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Aripiprazole	Tablet 30 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand
Atenolol	Oral solution 50 mg in 10 mL, 300 mL	Oral	Atenolol-AFT	4 months stock by reference to usual PBS demand
Atenolol	Tablet 50 mg	Oral	APX-Atenolol	4 months stock by reference to usual demand
Atenolol	Tablet 50 mg	Oral	Tensig	4 months stock by reference to usual demand
Atomoxetine	Capsule 10 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
Atomoxetine	Capsule 100 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
Atomoxetine	Capsule 18 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
Atomoxetine	Capsule 25 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
Atomoxetine	Capsule 40 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
Atomoxetine	Capsule 60 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
Atomoxetine	Capsule 80 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
Atorvastatin	Tablet 10 mg (as calcium)	Oral	Atorvastatin GH	between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Atorvastatin	Tablet 40 mg (as calcium)	Oral	Atorvastatin GH	between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand
Azithromycin	Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL	Oral	Zithromax	4 months stock by reference to usual PBS demand
Baclofen	Tablet 10 mg	Oral	APO-Baclofen	3 months stock by reference to usual demand
Benzathine benzylpenicillin	Injection containing 1,200,000 units benzathine benzylpenicillin tetrahydrate in 2.3 mL single use pre-filled syringe	Injection	Bicillin L-A	6 months stock by reference to usual PBS demand
Benzathine benzylpenicillin	Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre-filled syringe	Injection	Bicillin L-A	6 months stock by reference to usual PBS demand
Bosentan	Tablet 125 mg (as monohydrate)	Oral	Bosentan APO	3 months stock by reference to usual demand
Bosentan	Tablet 125 mg (as monohydrate)	Oral	Bosentan Cipla	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand
Bosentan	Tablet 125 mg (as monohydrate)	Oral	Tracleer	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Bosentan	Tablet 62.5 mg (as monohydrate)	Oral	Tracleer	between 1 April 2024 and 31 May 2024— 0 months stock by reference to usual demand
Calcium	Tablet, chewable, 500 mg (as carbonate)	Oral	Cal-500	after 30 November 2023—6 months stock by reference to usual PBS demand
Candesartan	Tablet containing candesartan cilexetil 16 mg	Oral	NOUMED CANDESARTAN	between 1 April 2024 and 30 June 2024— 0 months stock by reference to usual demand
Candesartan	Tablet containing candesartan cilexetil 32 mg	Oral	NOUMED CANDESARTAN	between 1 April 2024 and 30 June 2024— 0 months stock by reference to usual demand
Candesartan	Tablet containing candesartan cilexetil 4 mg	Oral	NOUMED CANDESARTAN	between 1 April 2024 and 30 June 2024— 0 months stock by reference to usual demand
Candesartan	Tablet containing candesartan cilexetil 8 mg	Oral	NOUMED CANDESARTAN	between 1 April 2024 and 30 June 2024— 0 months stock by reference to usual demand
Capecitabine	Tablet 150 mg	Oral	Capecitabine-DRLA	between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand
Captopril	Oral solution 5 mg per mL, 95 mL	Oral	Capoten	4 months stock by reference to usual PBS demand
Carmellose	Eye drops containing carmellose sodium 10 mg per mL, 15 mL	Application to the Eye	Refresh Liquigel	4 months stock by reference to usual PBS demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administrati on	Column 4 Brand	Column 5 Applicable quantity
Carmellose	Eye drops containing carmellose sodium 5 mg per mL, 15 mL	Application to the Eye	Refresh Tears Plus	4 months stock by reference to usual PBS demand
Carmellose with glycerin	Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL	Application to the Eye	Optive	4 months stock by reference to usual PBS demand
Cefazolin	Powder for injection 2 g (as sodium)	Injection	Cephazolin Viartis	after 30 July 2024—6 months stock by reference to usual demand of both Cephazolin Viartis and Cephazolin Alphapharm added together
Cefazolin	Powder for injection 500 mg (as sodium)	Injection	Cefazolin-AFT	between 1 May 2024 and 30 July 2024—0 months stock by reference to usual demand
Cefepime	Powder for injection 1 g (as hydrochloride)	Injection	Omegapharm Pty Ltd	between 1 May 2024 and 31 May 2024—0 months stock by reference to usual demand
Cefepime	Powder for injection 2 g (as hydrochloride)	Injection	Omegapharm Pty Ltd	between 1 May 2024 and 31 May 2024—0 months stock by reference to usual demand
Ceftriaxone	Powder for injection 1 g (as sodium)	Injection	Ceftriaxone Viartis	after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viartis and Ceftriaxone Alphapharm added together

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Ceftriaxone	Powder for injection 2 g (as sodium)	Injection	Ceftriaxone Viartis	after 31 May 2024— 6 months stock by reference to usual demand of both Ceftriaxone Viartis and Ceftriaxone Alphapharm added together
Chloramphenicol	Eye drops 5 mg per mL, 10 mL	Application to the Eye	Chlorsig	4 months stock by reference to usual PBS demand
Chlorpromazine	Tablet containing chlorpromazine hydrochloride 25 mg	Oral	Largactil	4 months stock by reference to usual PBS demand
Chlortalidone	Tablet 25 mg	Oral	Hygroton 25	4 months stock by reference to usual PBS demand
Ciclosporin	Capsule 10 mg	Oral	Neoral 10	4 months stock by reference to usual PBS demand
Ciclosporin	Capsule 100 mg	Oral	APO-Ciclosporin	2.5 months stock by reference to usual demand
Ciclosporin	Capsule 25 mg	Oral	APO-Ciclosporin	3 months stock by reference to usual demand
Ciclosporin	Capsule 50 mg	Oral	APO-Ciclosporin	3 months stock by reference to usual demand
Ciclosporin	Oral liquid 100 mg per mL, 50 mL	Oral	Neoral	4 months stock by reference to usual PBS demand
Clarithromycin	Powder for oral liquid 250 mg per 5 mL, 50 mL	Oral	Klacid	4 months stock by reference to usual PBS demand
Clindamycin	Capsule 150 mg (as hydrochloride)	Oral	Clindamycin BNM	between 1 April 2024 and 30 June 2024— 0 months stock by reference to usual demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administrati on	Column 4 Brand	Column 5 Applicable quantity
Clonazepam	Oral liquid 2.5 mg per mL, 10 mL	Oral	Rivotril	6 months stock by reference to usual PBS demand
Codeine	Tablet containing codeine phosphate hemihydrate 30 mg	Oral	Aspen Pharma Pty Ltd	4 months stock by reference to usual PBS demand
Dantrolene	Capsule containing dantrolene sodium hemiheptahydrate 25 mg	Oral	Dantrium	6 months stock by reference to usual PBS demand
Diazepam	Oral liquid 10 mg per 10 mL, 100 mL	Oral	Diazepam Elixir	4 months stock by reference to usual PBS demand
Diphtheria and tetanus vaccine, adsorbed, diluted for adult use	Injection 0.5 mL in pre-filled syringe	Injection	ADT Booster	6 months stock by reference to usual PBS demand
Dolutegravir with abacavir and lamivudine	Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg	Oral	Triumeq	after 30 November 2023—6 months stock by reference to usual PBS demand
Dosulepin	Capsule containing dosulepin hydrochloride 25 mg	Oral	Dosulepin Viatris	after 31 May 2024—6 months stock by reference to usual demand of both Dosulepin Viatris and Dosulepin Mylan added together
Dosulepin	Tablet containing dosulepin hydrochloride 75 mg	Oral	Dosulepin Viatris 75	6 months stock by reference to usual demand of both Dosulepin Viatris 75 and Dosulepin Mylan added together

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Doxorubicin - pegylated liposomal	Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL	Injection	Liposomal Doxorubicin SUN	3 months stock by reference to usual demand
Doxorubicin - pegylated liposomal	Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL	Injection	Liposomal Doxorubicin SUN	3 months stock by reference to usual demand
Doxycycline	Tablet 100 mg (as hyclate)	Oral	APX-Doxycycline	(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand
Doxycycline	Tablet 50 mg (as hyclate)	Oral	Doxsig	4 months stock by reference to usual demand
Enalapril	Tablet containing enalapril maleate 10 mg	Oral	APO-Enalapril	4 months stock by reference to usual demand
Enalapril	Tablet containing enalapril maleate 10 mg	Oral	Enalapril generichealth	between 1 February 2024 and 31 May 2024—0 months stock by reference to usual demand
Enalapril	Tablet containing enalapril maleate 10 mg	Oral	Malean	4 months stock by reference to usual demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administrati on	Column 4 Brand	Column 5 Applicable quantity
Enalapril	Tablet containing enalapril maleate 20 mg	Oral	APO-Enalapril	3 months stock by reference to usual demand
Enalapril	Tablet containing enalapril maleate 20 mg	Oral	Malean	3 months stock by reference to usual demand
Enalapril	Tablet containing enalapril maleate 5 mg	Oral	Acetec	(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand
Enalapril	Tablet containing enalapril maleate 5 mg	Oral	APO-Enalapril	4 months stock by reference to usual demand
Enalapril	Tablet containing enalapril maleate 5 mg	Oral	Enalapril generichealth	between 1 February 2024 and 31 May 2024—0 months stock by reference to usual demand
Enalapril	Tablet containing enalapril maleate 5 mg	Oral	Malean	4 months stock by reference to usual demand
Escitalopram	Oral solution 20 mg (as oxalate) per mL, 15 mL	Oral	Lexapro	4 months stock by reference to usual PBS demand
Escitalopram	Tablet 10 mg (as oxalate)	Oral	APX-Escitalopram	4 months stock by reference to usual demand
Escitalopram	Tablet 20 mg (as oxalate)	Oral	APX-Escitalopram	4 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-10 mg	Oral	APO-Ezetimibe/Simvastatin 10/10	3 months stock by reference to usual demand

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Ezetimibe with simvastatin	Tablet 10 mg-10 mg	Oral	EZETORIN	3 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-20 mg	Oral	APO-Ezetimibe/Simvastatin 10/20	3 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-20 mg	Oral	EZETORIN	3 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-40 mg	Oral	APO-Ezetimibe/Simvastatin 10/40	3 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-40 mg	Oral	EZETORIN	3 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-80 mg	Oral	APO-Ezetimibe/Simvastatin 10/80	3 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-80 mg	Oral	EZETORIN	3 months stock by reference to usual demand
Felodipine	Tablet 2.5 mg (extended release)	Oral	Felodur ER 2.5 mg	2.5 months stock by reference to usual demand
Felodipine	Tablet 2.5 mg (extended release)	Oral	Plendil ER	2.5 months stock by reference to usual demand
Fenofibrate	Tablet 145 mg	Oral	Fenofibrate Viatriis	6 months stock by reference to usual demand of both Fenofibrate Viatriis and Fenofibrate Mylan added together

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administrati on	Column 4 Brand	Column 5 Applicable quantity
Fentanyl	Transdermal patch 10.20 mg	Transdermal	Denpax	(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by reference to usual demand
Fentanyl	Transdermal patch 12.6 mg	Transdermal	APO-Fentanyl	3 months stock by reference to usual demand
Fentanyl	Transdermal patch 16.8 mg	Transdermal	APO-Fentanyl	3 months stock by reference to usual demand
Fentanyl	Transdermal patch 2.1 mg	Transdermal	APO-Fentanyl	(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand
Fentanyl	Transdermal patch 4.2 mg	Transdermal	APO-Fentanyl	3 months stock by reference to usual demand

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Fentanyl	Transdermal patch 5.10 mg	Transdermal	Denpax	(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by reference to usual demand
Fentanyl	Transdermal patch 8.4 mg	Transdermal	APO-Fentanyl	3 months stock by reference to usual demand
Fluconazole	Powder for oral suspension 50 mg in 5 mL, 35 mL	Oral	Diflucan	4 months stock by reference to usual PBS demand
Fluorometholone	Eye drops 1 mg per mL, 5 mL	Application to the Eye	FML Liquifilm	2 months stock by reference to usual PBS demand
Fluorometholone	Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL	Application to the Eye	Flarex	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual PBS demand
Folic acid	Tablet 5 mg	Oral	Megafol 5	4 months stock by reference to usual PBS demand
Folic acid	Tablet 500 micrograms	Oral	Foltabs 500	4 months stock by reference to usual PBS demand
Folic acid	Tablet 500 micrograms	Oral	Megafol 0.5	4 months stock by reference to usual PBS demand
Fosinopril	Tablet containing fosinopril sodium 10 mg	Oral	APO-Fosinopril	3 months stock by reference to usual demand
Fosinopril	Tablet containing fosinopril sodium 20 mg	Oral	APO-Fosinopril	3 months stock by reference to usual demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Framycetin	Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL	Application to the Eye/Ear	Soframycin	4 months stock by reference to usual PBS demand
Furosemide	Oral solution 10 mg per mL, 30 mL	Oral	Lasix	4 months stock by reference to usual PBS demand
Gabapentin	Capsule 400 mg	Oral	GAPENTIN	3 months stock by reference to usual demand
Galantamine	Capsule (prolonged release) 16 mg (as hydrobromide)	Oral	Gamine XR	3 months stock by reference to usual demand
Galantamine	Capsule (prolonged release) 24 mg (as hydrobromide)	Oral	Gamine XR	3 months stock by reference to usual demand
Galantamine	Capsule (prolonged release) 8 mg (as hydrobromide)	Oral	Galantyl	(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—1.5 months stock by reference to usual demand
Galantamine	Capsule (prolonged release) 8 mg (as hydrobromide)	Oral	Gamine XR	3 months stock by reference to usual demand
Glucose and ketone indicator-urine	Test strips, 50 (Keto-Diastix)	For External Use	Keto-Diastix	4 months stock by reference to usual PBS demand
Haloperidol	Tablet 1.5 mg	Oral	Serenace	4 months stock by reference to usual PBS demand

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Haloperidol	Tablet 5 mg	Oral	Serenace	4 months stock by reference to usual PBS demand
Haloperidol	Tablet 500 micrograms	Oral	Serenace	4 months stock by reference to usual PBS demand
Heparin	Injection 5,000 units (as sodium) in 0.2 ml	Injection	DBL Heparin Sodium	6 months stock by reference to usual PBS demand
Hydrocortisone	Tablet 20 mg	Oral	Hydrocortisone Viatrix 20	4 months stock by reference to usual demand of both Hydrocortisone Viatrix 20 and Hydrocortisone Mylan 20 added together
Hypromellose	Eye drops 3 mg per mL, 10 mL	Application to the Eye	Genteal	4 months stock by reference to usual demand
Hypromellose	Eye drops 3 mg per mL, 10 mL	Application to the Eye	In a Wink Moisturising	4 months stock by reference to usual demand
Imatinib	Capsule 100 mg (as mesilate)	Oral	Imatinib-APOTEX	3 months stock by reference to usual demand
Imatinib	Capsule 400 mg (as mesilate)	Oral	Imatinib-APOTEX	3 months stock by reference to usual demand
Indapamide	Tablet containing indapamide hemihydrate 2.5 mg	Oral	Insig	3 months stock by reference to usual demand
Insect allergen extract-honey bee venom	Injection set containing 550 micrograms with diluent	Injection	Hymenoptera Honey Bee Venom	after 30 November 2023—6 months stock by reference to usual PBS demand
Insect allergen extract-paper wasp venom	Injection set containing 550 micrograms with diluent	Injection	Hymenoptera Paper Wasp Venom	after 30 November 2023—6 months stock by reference to usual PBS demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Insect allergen extract-yellow jacket venom	Injection set containing 550 micrograms with diluent	Injection	Hymenoptera Yellow Jacket Venom	after 30 November 2023—6 months stock by reference to usual PBS demand
Lamivudine with zidovudine	Tablet 150 mg-300 mg	Oral	Lamivudine/Zidovudine Viatris 150/300	after 31 May 2024—4 months stock by reference to usual demand of both Lamivudine/Zidovudine Viatris 150/300 and Lamivudine 150 mg + Zidovudine 300 mg Alphapharm added together
Lansoprazole	Tablet 15 mg (orally disintegrating)	Oral	APO-Lansoprazole ODT	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand
Lansoprazole	Tablet 30 mg (orally disintegrating)	Oral	APO-Lansoprazole ODT	3 months stock by reference to usual demand
Latanoprost	Eye drops 50 micrograms per mL, 2.5 mL	Application to the Eye	APO-Latanoprost	2 months stock by reference to usual demand
Latanoprost with timolol	Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL	Application to the Eye	APO-Latanoprost/Timolol 0.05/5	2.5 months stock by reference to usual demand
Lithium	Tablet containing lithium carbonate 250 mg	Oral	Lithicarb	after 30 November 2023—6 months stock by reference to usual PBS demand

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Lithium	Tablet containing lithium carbonate 450 mg (slow release)	Oral	Quilonum SR	after 30 November 2023—6 months stock by reference to usual PBS demand
Meloxicam	Tablet 7.5 mg	Oral	MELOBIC	4 months stock by reference to usual demand
Methoxyflurane	Liquid for inhalation 999 mg per g, 3 ml (with inhaler)	Inhalation by mouth	Penthrox	6 months stock by reference to usual PBS demand
Methylprednisolone	Injection containing methylprednisolone acetate 40 mg in 1 mL	Injection	Depo-Nisolone	between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand
Metoprolol	Tablet containing metoprolol tartrate 100 mg	Oral	Metrol 100	4 months stock by reference to usual demand
Metronidazole	Suppositories 500 mg, 10	Rectal	Flagyl	6 months stock by reference to usual PBS demand
Milk protein and fat formula with vitamins and minerals -- carbohydrate free	Oral powder 225 g (Carbohydrate Free Mixture)	Oral	Carbohydrate Free Mixture	6 months stock by reference to usual PBS demand
Mitozantrone	Injection 25 mg (as hydrochloride) in 12.5 mL	Injection	Onkotrone	between 1 May 2024 and 30 July 2024—0 months stock by reference to usual demand
Modafinil	Tablet 100 mg	Oral	Modafin	3 months stock by reference to usual demand
Morphine	Tablet containing morphine sulfate pentahydrate 30 mg	Oral	Anamorph	3 months stock by reference to usual demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administrati on	Column 4 Brand	Column 5 Applicable quantity
Moxonidine	Tablet 200 micrograms	Oral	Moxonidine Viatris	4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together
Moxonidine	Tablet 400 micrograms	Oral	Moxonidine Viatris	4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together
Mycophenolic acid	Capsule containing mycophenolate mofetil 250 mg	Oral	CellCept	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand
Mycophenolic acid	Tablet containing mycophenolate mofetil 500 mg	Oral	CellCept	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand
Mycophenolic acid	Tablet containing mycophenolate mofetil 500 mg	Oral	Noumed Mycophenolate	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand
Nevirapine	Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL	Oral	Viramune	4 months stock by reference to usual PBS demand
Nicorandil	Tablets 10 mg, 60	Oral	APO-Nicorandil	2 months stock by reference to usual demand

Applicable quantity of a brand of a pharmaceutical item **Schedule 1**

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Nicorandil	Tablets 10 mg, 60	Oral	Ikotab	(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand
Nicorandil	Tablets 20 mg, 60	Oral	APO-Nicorandil	2 months stock by reference to usual demand
Nicorandil	Tablets 20 mg, 60	Oral	Ikotab	(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand
Norfloxacin	Tablet 400 mg	Oral	APO-Norfloxacin	2.5 months stock by reference to usual demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item

Column 1 Drug	Column 2 Form	Column 3 Manner of administrati on	Column 4 Brand	Column 5 Applicable quantity
Olanzapine	Tablet 10 mg (orally disintegrating)	Oral	Zypine ODT	(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 10 mg (orally disintegrating), Oral, added together

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Olanzapine	Tablet 15 mg (orally disintegrating)	Oral	PRYZEX ODT	(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand
Olanzapine	Tablet 15 mg (orally disintegrating)	Oral	Zypine ODT	(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 15 mg (orally disintegrating), Oral, added together.

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Olanzapine	Tablet 20 mg (orally disintegrating)	Oral	Zypine ODT	(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 20 mg (orally disintegrating), Oral, added together
Olanzapine	Tablet 5 mg (orally disintegrating)	Oral	APO-Olanzapine ODT	3 months stock by reference to usual demand

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Olanzapine	Tablet 5 mg (orally disintegrating)	Oral	Zypine ODT	(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 5 mg (orally disintegrating), Oral, added together
Olmesartan	Tablet containing olmesartan medoxomil 20 mg	Oral	OLMERTAN	3 months stock by reference to usual demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Olmesartan	Tablet containing olmesartan medoxomil 40 mg	Oral	OLMERTAN	(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand
Olmesartan with hydrochlorothiazide	Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg	Oral	OLMERTAN COMBI 20/12.5	3 months stock by reference to usual demand
Olmesartan with hydrochlorothiazide	Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg	Oral	OLMERTAN COMBI 40/12.5	3 months stock by reference to usual demand
Olmesartan with hydrochlorothiazide	Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg	Oral	OLMERTAN COMBI 40/25	3 months stock by reference to usual demand
Ondansetron	Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL	Oral	Zofran syrup 50 mL	4 months stock by reference to usual PBS demand
Oxazepam	Tablet 30 mg	Oral	APO-Oxazepam	5.5 months stock by reference to usual demand
Oxazepam	Tablet 30 mg	Oral	Murelax	5 months stock by reference to usual demand

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Oxycodone	Oral solution containing oxycodone hydrochloride 1 mg per mL, 1 mL	Oral	OxyNorm Liquid 1mg/mL	4 months stock by reference to usual PBS demand
Oxycodone	Tablet containing oxycodone hydrochloride 5 mg	Oral	Oxycodone Viatris	after 28 February 2024—6 months stock by reference to usual demand of both Oxycodone Viatris and Oxycodone Mylan added together
Pantoprazole	Sachet containing granules 40 mg (as sodium sesquihydrate)	Oral	Somac	4 months stock by reference to usual PBS demand
Pantoprazole	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	Oral	APO-Pantoprazole	(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand
Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	Sozol	(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administrati on	Column 4 Brand	Column 5 Applicable quantity
Paraffin with retinol palmitate	Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinol palmitate, 5 g	Application to the Eye	VitA-POS	between 1 April 2024 and 30 September 2024—0 months stock by reference to usual demand
Periciazine	Tablet 2.5 mg	Oral	Neulactil	4 months stock by reference to usual PBS demand
Perindopril	Tablet containing perindopril erbumine 2 mg	Oral	Indosyl Mono 2	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand
Perindopril	Tablet containing perindopril erbumine 4 mg	Oral	Indosyl Mono 4	(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Perindopril with indapamide	Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg	Oral	Indosyl Combi 4/1.25	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand
Perindopril with indapamide	Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg	Oral	Perindo Combi 4/1.25	(a) between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by reference to usual demand
Permethrin	Cream 50 mg per g, 30 g	Application	Lyclear	after 30 November 2023—6 months stock by reference to usual PBS demand
Pimecrolimus	Cream 10 mg per g, 15 g	Application	Elidel	6 months stock by reference to usual PBS demand
Pioglitazone	Tablet 30 mg (as hydrochloride)	Oral	NOUMED PIOGLITAZONE	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand
Pioglitazone	Tablet 30 mg (as hydrochloride)	Oral	Pioglitazone Sandoz	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand
Pioglitazone	Tablet 45 mg (as hydrochloride)	Oral	NOUMED PIOGLITAZONE	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Pioglitazone	Tablet 45 mg (as hydrochloride)	Oral	Pioglitazone Sandoz	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand
Pregabalin	Capsule 25 mg	Oral	Cipla Pregabalin	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand
Pregabalin	Capsule 300 mg	Oral	Cipla Pregabalin	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand
Pregabalin	Capsule 75 mg	Oral	Cipla Pregabalin	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand
Probenecid	Tablet 500 mg	Oral	Pro-Cid	after 30 November 2023—6 months stock by reference to usual PBS demand
Prochlorperazine	Injection containing prochlorperazine mesilate 12.5 mg in 1 mL	Injection	Stemetil	6 months stock by reference to usual PBS demand
Protein hydrolysate formula with medium chain triglycerides	Oral powder 450 g (Aptamil Gold+ Pepti-Junior)	Oral	Aptamil Gold+ Pepti-Junior	6 months stock by reference to usual PBS demand
Quinapril	Tablet 10 mg (as hydrochloride)	Oral	APO-Quinapril	3 months stock by reference to usual demand
Quinapril	Tablet 20 mg (as hydrochloride)	Oral	APO-Quinapril	3 months stock by reference to usual demand

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Rabeprazole	Tablet containing rabeprazole sodium 10 mg (enteric coated)	Oral	APO-Rabeprazole	4 months stock by reference to usual demand
Rabeprazole	Tablet containing rabeprazole sodium 10 mg (enteric coated)	Oral	Parbezol	4 months stock by reference to usual demand
Raloxifene	Tablet containing raloxifene hydrochloride 60 mg	Oral	RALOVISTA	3 months stock by reference to usual demand
Ramipril	Capsule 10 mg	Oral	APX-Ramipril	(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand
Ramipril	Capsule 10 mg	Oral	Prilace	(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand
Ramipril	Tablet 1.25 mg	Oral	Prilace	2.5 months stock by reference to usual demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administrati on	Column 4 Brand	Column 5 Applicable quantity
Ramipril	Tablet 1.25 mg	Oral	Tryzan Tabs 1.25	(a) between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand (b) after 31 December 2023—3 months stock by reference to usual demand
Ramipril with felodipine	Tablet 2.5 mg-2.5 mg (modified release)	Oral	Triasyn 2.5/2.5	4 months stock by reference to usual PBS demand
Riluzole	Oral suspension 50 mg per 10 mL, 300 mL	Oral	Teglutik	between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand
Risedronic acid	Tablet containing risedronate sodium 150 mg	Oral	APO-Risedronate	3 months stock by reference to usual demand
Risperidone	Tablet 3 mg	Oral	APO-Risperidone	(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand
Risperidone	Tablet 3 mg	Oral	Rispa	3 months stock by reference to usual demand
Rosuvastatin	Tablet 10 mg (as calcium)	Oral	Noumed Rosuvastatin	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Rosuvastatin	Tablet 20 mg (as calcium)	Oral	Noumed Rosuvastatin	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand
Rosuvastatin	Tablet 40 mg (as calcium)	Oral	Noumed Rosuvastatin	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand
Rosuvastatin	Tablet 5 mg (as calcium)	Oral	Noumed Rosuvastatin	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand
Roxithromycin	Tablet 150 mg	Oral	APX-Roxithromycin	4 months stock by reference to usual demand
Roxithromycin	Tablet 150 mg	Oral	Roximycin	between 1 May 2024 and 30 June 2024—0 months stock by reference to usual demand
Roxithromycin	Tablet 300 mg	Oral	APX-Roxithromycin	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand
Roxithromycin	Tablet 300 mg	Oral	Roximycin	between 1 May 2024 and 30 June 2024—0 months stock by reference to usual demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)	Inhalation by Mouth	Asmol CFC-Free with dose counter	between 1 January 2024 and 30 June 2024—0 months stock by reference to usual demand
Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)	Inhalation by Mouth	Zempreon CFC-Free with dose counter	between 1 January 2024 and 30 June 2024—0 months stock by reference to usual demand
Sodium acid phosphate	Tablet, compound effervescent, equivalent to 500 mg phosphorus	Oral	PHOSPHATE PHEBRA	after 30 November 2023—6 months stock by reference to usual PBS demand
Sotalol	Tablet containing sotalol hydrochloride 160 mg	Oral	Cardol	(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—1.5 months stock by reference to usual demand
Sumatriptan	Tablet 50 mg (as succinate)	Oral	APO-Sumatriptan	4 months stock by reference to usual demand
Tacrolimus	Capsule 1 mg	Oral	Tacrograf	3 months stock by reference to usual demand
Tacrolimus	Capsule 5 mg	Oral	Tacrograf	3 months stock by reference to usual demand

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Temazepam	Tablet 10 mg	Oral	APO-Temazepam	2.5 months stock by reference to usual demand
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	Oral	Tenofovir/Emtricitabine 300/200 APOTEX	3 months stock by reference to usual demand
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg	Oral	Tenofovir Disoproxil Emtricitabine Viartis 300/200	after 30 April 2024—4 months stock by reference to usual demand of both Tenofovir Disoproxil Emtricitabine Viartis 300/200 and Tenofovir Disoproxil Emtricitabine Mylan 300/200 added together
Thiamine	Tablet containing thiamine hydrochloride 100 mg	Oral	Betavit	4 months stock by reference to usual PBS demand
Tobramycin	Injection 80 mg (as sulfate) in 2 mL (without preservative)	Injection	Pfizer Australia Pty Ltd	between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand
Tobramycin	Injection 80 mg in 2 mL	Injection	Tobramycin Viartis	4 months stock by reference to usual demand of both Tobramycin Viartis and Tobramycin Mylan added together
Topiramate	Tablet 100 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Topiramate	Tablet 100 mg	Oral	NOUMED TOPIRAMATE	between 1 April 2024 and 30 June 2024— 0 months stock by reference to usual demand
Topiramate	Tablet 200 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand
Topiramate	Tablet 200 mg	Oral	NOUMED TOPIRAMATE	between 1 April 2024 and 30 June 2024— 0 months stock by reference to usual demand
Topiramate	Tablet 25 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand
Topiramate	Tablet 25 mg	Oral	NOUMED TOPIRAMATE	between 1 April 2024 and 30 June 2024— 0 months stock by reference to usual demand
Topiramate	Tablet 50 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand
Topiramate	Tablet 50 mg	Oral	NOUMED TOPIRAMATE	between 1 April 2024 and 30 June 2024— 0 months stock by reference to usual demand
Tramadol	Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL	Oral	Tramal	4 months stock by reference to usual PBS demand
Trandolapril	Capsule 1 mg	Oral	Dolapril 1	3 months stock by reference to usual demand
Trandolapril	Capsule 2 mg	Oral	Dolapril 2	3 months stock by reference to usual demand

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administration	Column 4 Brand	Column 5 Applicable quantity
Trandolapril	Capsule 4 mg	Oral	Dolapril 4	3 months stock by reference to usual demand
Trandolapril	Capsule 500 micrograms	Oral	Dolapril 0.5	2.5 months stock by reference to usual demand
Triglycerides—medium chain, formula	Oral powder 400 g (Lipistart)	Oral	Lipistart	0 months stock by reference to usual PBS demand
Triglycerides, medium chain	Oral liquid 225 mL, 15 (K.Quik)	Oral	K.Quik	0 months stock by reference to usual PBS demand
Trimethoprim	Tablet 300 mg	Oral	Trimethoprim Viatriis	after 30 April 2024—6 months stock by reference to usual demand of both Trimethoprim Viatriis and Trimethoprim Mylan added together
Valaciclovir	Tablet 500 mg (as hydrochloride)	Oral	NOUMED VALACICLOVIR	between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand
Valganciclovir	Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL	Oral	Valcyte	4 months stock by reference to usual PBS demand
Valganciclovir	Tablet 450 mg (as hydrochloride)	Oral	Valganciclovir Viatriis	4 months stock by reference to usual demand of both Valganciclovir Viatriis and Valganciclovir Mylan added together
Valproic acid	Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL	Oral	Epilim Liquid	6 months stock by reference to usual PBS demand

Schedule 1 Applicable quantity of a brand of a pharmaceutical item

Applicable quantity of a brand of a pharmaceutical item				
Column 1 Drug	Column 2 Form	Column 3 Manner of administrati on	Column 4 Brand	Column 5 Applicable quantity
Valproic acid	Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL	Oral	Epilim Syrup	6 months stock by reference to usual PBS demand
Valproic acid	Tablet, crushable, containing sodium valproate 100 mg	Oral	Epilim	4 months stock by reference to usual PBS demand
Voriconazole	Powder for oral suspension 40 mg per mL, 70 mL	Oral	Vfend	4 months stock by reference to usual PBS demand

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes

The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the *Legislation Act 2003*.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.

Endnotes

Endnote 2—Abbreviation key

Endnote 2—Abbreviation key

ad = added or inserted	o = order(s)
am = amended	Ord = Ordinance
amdt = amendment	orig = original
c = clause(s)	par = paragraph(s)/subparagraph(s) /sub-subparagraph(s)
C[x] = Compilation No. x	pres = present
Ch = Chapter(s)	prev = previous
def = definition(s)	(prev...) = previously
Dict = Dictionary	Pt = Part(s)
disallowed = disallowed by Parliament	r = regulation(s)/rule(s)
Div = Division(s)	reloc = relocated
ed = editorial change	renum = renumbered
exp = expires/expired or ceases/ceased to have effect	rep = repealed
F = Federal Register of Legislation	rs = repealed and substituted
gaz = gazette	s = section(s)/subsection(s)
LA = <i>Legislation Act 2003</i>	Sch = Schedule(s)
LIA = <i>Legislative Instruments Act 2003</i>	Sdiv = Subdivision(s)
(md) = misdescribed amendment can be given effect	SLI = Select Legislative Instrument
(md not incorp) = misdescribed amendment cannot be given effect	SR = Statutory Rules
mod = modified/modification	Sub-Ch = Sub-Chapter(s)
No. = Number(s)	SubPt = Subpart(s)
	<u>underlining</u> = whole or part not commenced or to be commenced

Endnote 3—Legislation history

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Minimum Stockholding) Determination 2023 (PB 65 of 2023)	30 June 2023 (F2023L00919)	1 July 2023 (s 2(1) item 1)	
National Health (Minimum Stockholding) Amendment Determination (No. 1) 2023 (PB 103 of 2023)	29 Sept 2023 (F2023L01338)	1 Oct 2023 (s 2(1) item 1)	—
National Health (Minimum Stockholding) Amendment Determination (No. 2) 2023 (PB 111 of 2023)	31 Oct 2023 (F2023L01455)	1 Nov 2023 (s 2(1) item 1)	—
National Health (Minimum Stockholding) Amendment Determination (No. 3) 2023 (PB 125 of 2023)	30 Nov 2023 (F2023L01573)	1 Dec 2023 (s 2(1) item 1)	—
National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023 (PB 136 of 2023)	18 Dec 2023 (F2023L01702)	Sch 2: 1 Feb 2024 (s 2(1) item 3) Sch 3: 1 Apr 2024 (s 2(1) item 4) Remainder: 1 Jan 2024 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 1) 2024 (PB 10 of 2024)	31 Jan 2024 (F2024L00114)	Sch 2: 1 June 2024 (s 2(1) item 3) Remainder: 1 Feb 2024 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 2) 2024 (PB 24 of 2024)	29 Feb 2024 (F2024L00228)	1 Mar 2024 (s 2(1) items 1, 2)	—
National Health (Minimum Stockholding) Amendment Determination (No. 3) 2024 (PB 32 of 2024)	28 Mar 2024 (F2024L00411)	1 Apr 2024 (s 2(1) items 1, 2, 3)	—
National Health (Minimum Stockholding) Amendment Determination (No.4) 2024 (PB 49 of 2024)	30 Apr 2024 (F2024L00502)	Sch 2: 1 Oct 2024 (s 2(1) item 3) Remainder: 1 May 2024 (s 2(1) items 1, 2)	—

Endnotes

Endnote 4—Amendment history

Endnote 4—Amendment history

Provision affected	How affected
Part 1	
s 2.....	rep LA s 48D
s 5.....	am F2023L01338
Schedule 1	
Schedule 1.....	am F2023L01338
	rs F2023L01455
	am F2023L01455; F2023L01573
	ed C3
	am F2023L01702; F2024L00114 (Sch 2)
	ed C5
	am F2024L00228; F2024L00411; F2024L00502 (Sch 2)
